Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 28,13 € (+58,57%). La mediana è 29,04 € (+63,70%).
| Acquista |
7 |
| Mantieni |
13 |
| Vendi |
0 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
JPMorgan rates Hims & Hers neutral and sees risks in shift to branded GLP‑1s
JPMorgan initiated coverage of Hims & Hers with a neutral rating and a $32 price target for December 2027. The bank praises the rapid direct‑to‑consumer growth but sees execution risks in the strategic pivot to approved branded GLP‑1 drugs rather than compounded formulations. Hims & Hers, in partnership with Novo Nordisk, fulfilled more than 125,000 Wegovy shipments in the first six weeks; JPMorgan forecasts $1.1bn in GLP‑1 revenue for 2026 and sees long‑term potential through 2030, but requires proof of successful execution, sustainable growth in new specialty areas, and margin expansion. » Altro su de.investing.com
Hims & Hers expands into Australia by renaming Pilot
Hims & Hers is introducing its brand in Australia by renaming the acquired men’s health platform Pilot to Hims. Existing Pilot patients will retain their treatment plans and providers; the offering includes sexual health, weight-loss and hair-loss treatments. The company has expanded customer support to 24/7, introduced new treatment combinations and clinical pathways, and is reorganizing leadership for the market. Hims & Hers acquired Eucalyptus in early 2026; the announcement notes integration, competitive and retention risks. » Altro su de.investing.com
Hims & Hers placed in Visa monitoring program after spike in weight-loss subscription disputes
Visa enrolled Hims & Hers in its Acquirer Monitoring Program after dispute rates for the company’s weight-loss subscriptions exceeded Visa’s 1.5% threshold. Hims faces an ~$75,000 surcharge in September and must keep disputes below 1.5% for three consecutive months to exit the program. The action compounds regulatory pressure from a recent FTC lawsuit over billing and cancellation practices, though Hims says disputed charges are a small number and is taking corrective steps. Shares tumbled after the news despite strong subscriber growth and rising revenue alongside widening losses and margin pressure. » Altro su finance.yahoo.com
Hims & Hers in Visa monitoring program after rise in credit card complaints
Hims & Hers was placed in Visa's Acquirer Monitoring Program after the number of credit card complaints in its subscription business for weight-loss products exceeded allowable thresholds in July. Each complaint carries an $8 penalty fee, which, according to internal documents, could result in a bill of nearly $75,000 due in September. Visa is demanding that the complaint rate be reduced to under 1.5% of transactions for three consecutive months; Hims & Hers says the number of disputed charges is relatively small and that it has implemented measures to improve the checkout process. » Altro su de.investing.com
Hims & Hers Health insider sells 21,500 shares to cover tax withholding after RSU vesting
Chief legal officer Soleil Boughton reported a non‑discretionary sale of 21,500 Hims & Hers Health shares on August 14 to satisfy tax withholding tied to vested restricted stock units, raising about $605,000 at $28.15 per share. Boughton retains 339,075 directly held shares and additional vested and unvested awards. The company faces a recent FTC lawsuit (a $47.5 million legal contingency) even as revenue grew 38% last quarter and management raised full‑year guidance, while the stock is down about 40% over the past year. » Altro su finance.yahoo.com
Dati finanziari dell'azienda
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 786,07 Mln | 54,01% |
| Utile lordo | 449,55 Mln | 19,34% |
| Utile netto | -29,17 Mln | 317,01% |
| EBITDA | -7,1 Mln | 127,87% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 4,03 Mld € |
Numero di azioni | 224,94 Mln |
Massimo/minimo a 52 settimane | 37,19 € - 12,47 € |
| Dividendi | No |
Beta | 2,50 |
Rapporto P/E | -24,06 |
Rapporto PEG | 0,54 |
Rapporto P/B | 12,98 |
Rapporto P/S | 1,55 |
Profilo aziendale
Hims & Hers Health, Inc. gestisce una piattaforma di telemedicina multispecialistica che mette in contatto i consumatori con professionisti sanitari abilitati. L'azienda offre una gamma di prodotti e servizi per la salute e il benessere, acquistabili direttamente dai clienti sui propri siti web e sull'applicazione mobile. Fornisce inoltre farmaci su prescrizione con una frequenza ricorrente e assistenza continuativa da parte di operatori sanitari; nonché farmaci da banco e dispositivi, cosmetici e integratori alimentari, con un focus principale su benessere, salute e benessere sessuale, cura della pelle e cura dei capelli. I prodotti non soggetti a prescrizione selezionati dall'azienda includono integratori di vitamina C, melatonina, biotina e proteine di collagene nella categoria benessere; crema idratante, sieri e detergente viso nella categoria cura della pelle; preservativi, spray e salviettine ritardanti dell'eiaculazione, vibratori e lubrificanti nella categoria salute e benessere sessuale; e shampoo, balsami, scrub per il cuoio capelluto e trattamenti topici, come il minoxidil, nella categoria cura dei capelli. Inoltre, offre servizi di consulenza medica, nonché prodotti per la salute e il benessere tramite partner all'ingrosso. L'azienda ha sede a San Francisco, in California.
| Nome | Hims & Hers Health |
| CEO | Andrew Dudum |
| Sede centrale | San Francisco,
ca Stati Uniti |
| Sito web | |
| Settore | Sanità |
| Industria | Fornitori e servizi sanitari |
| Quotazione in borsa | 13/09/2019 |
| Dipendenti | 2442 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NYSE | HIMS |
Frankfurt | 82W.F |
Düsseldorf | 82W.DU |
München | 82W.MU |